Lacutoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called lacutoclax (LP-108) in patients whose chronic lymphocytic leukemia or small lymphocytic lymphoma has stopped responding to previous treatments. The drug is designed to work differently than prior therapies and may help patients whose cancer has come back or become resistant to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has stopped responding to or come back after prior treatment
- You have received at least one prior standard cancer treatment before joining this study
- You have measurable disease that can be tracked on imaging or blood tests
- You are at least 18 years old and in reasonable overall health (able to carry out light activity)
- You have not received certain stem-cell transplants or CAR-T therapy within the past 3 months
- You agree to use effective birth control during the study and for 3 months after treatment ends (if able to become pregnant or father children)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Hear when a new Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.